This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nemunaitis, J. Articles by Roth, J. Search for Related Content PubMed PubMed Citation Articles by Nemunaitis, J. Articles by Roth, J. Social Bookmarking                            What's this?

Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non–Small-Cell Lung Cancer

From US Oncology, Baylor University Medical Center, and Columbia Medical City, Dallas; and Section of Thoracic Molecular Oncology, Departments of Diagnostic Imaging, Pathology, Thoracic/Head and Neck Medical Oncology, and Biomathematics, The University of Texas M.D. Anderson Cancer Center, and Introgen Therapeutics, Inc, Houston, TX.

Address reprint requests to John Nemunaitis, MD, Physician Reliance Network Research, Inc, 3535 Worth St, Collins Building, 5th Floor, Dallas, TX 75246; email j.nemunaitis{at}usoncology.com

PURPOSE: To determine the safety and tolerability of adenovirus-mediated p53 (Adp53) gene transfer in sequence with cisplatin when given by intratumor injection in patients with non–small-cell lung cancer (NSCLC).

PATIENTS AND METHODS: Patients with advanced NSCLC and abnormal p53 function were enrolled onto cohorts receiving escalating dose levels of Adp53 (1 x 10⁶ to 1 x 10¹¹ plaque-forming units [PFU]). Patients were administered intravenous cisplatin 80 mg/m² on day 1 and study vector on day 4 for a total of up to six courses (28 days per course). Apoptosis was determined by the terminal deoxynucleotidyl- transferase-dUTP nick–end labeling assay. Evidence of vector-specific sequences were determined using reverse-transcriptase polymerase chain reaction. Vector dissemination and biodistribution was monitored using a series of assays (cytopathic effects assay, Ad5 hexon enzyme-linked immunosorbent assay, vector-specific polymerase chain reaction assay, and antibody response assay).

RESULTS: Twenty-four patients (median age, 64 years) received a total of 83 intratumor injections with Adp53. The maximum dose administered was 1 x 10¹¹ PFU per dose. Transient fever related to Adp53 injection developed in eight of 24 patients. Seventeen patients achieved a best clinical response of stable disease, two patients achieved a partial response, four patients had progressive disease, and one patient was not assessable. A mean apoptotic index between baseline and follow-up measurements increased from 0.010 to 0.044 (P = .011). Intratumor transgene mRNA was identified in 43% of assessable patients.

CONCLUSION: Intratumoral injection with Adp53 in combination with cisplatin is well tolerated, and there is evidence of clinical activity.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H Schulze-Bergkamen, A Weinmann, M Moehler, J Siebler, and P R Galle Novel ways to sensitise gastrointestinal cancer to apoptosis Gut, July 1, 2009; 58(7): 1010 - 1024. [Abstract] [Full Text] [PDF]

				M. Idogawa, Y. Sasaki, H. Suzuki, H. Mita, K. Imai, Y. Shinomura, and T. Tokino A Single Recombinant Adenovirus Expressing p53 and p21-targeting Artificial microRNAs Efficiently Induces Apoptosis in Human Cancer Cells Clin. Cancer Res., June 1, 2009; 15(11): 3725 - 3732. [Abstract] [Full Text] [PDF]

				V. Keedy, W. Wang, J. Schiller, S. Chada, B. Slovis, K. Coffee, J. Worrell, L. A. Thet, D. H. Johnson, and D. P. Carbone Phase I Study of Adenovirus p53 Administered by Bronchoalveolar Lavage in Patients With Bronchioloalveolar Cell Lung Carcinoma: ECOG 6597 J. Clin. Oncol., September 1, 2008; 26(25): 4166 - 4171. [Abstract] [Full Text] [PDF]

				G. Wallraven, J. J. Nemunaitis, and P. B. Maples Compassionate Approval Process for Experimental Gene-Based Products J. Clin. Oncol., April 10, 2008; 26(11): 1899 - 1900. [Full Text] [PDF]

				N. Senzer, J. Nemunaitis, M. Nemunaitis, J. Lamont, M. Gore, H. Gabra, R. Eeles, N. Sodha, F. J. Lynch, L. A. Zumstein, et al. p53 therapy in a patient with Li-Fraumeni syndrome Mol. Cancer Ther., May 1, 2007; 6(5): 1478 - 1482. [Abstract] [Full Text] [PDF]

				H. Dvory-Sobol, E. Sagiv, D. Kazanov, A. Ben-Ze'ev, and N. Arber Targeting the active {beta}-catenin pathway to treat cancer cells. Mol. Cancer Ther., November 1, 2006; 5(11): 2861 - 2871. [Abstract] [Full Text] [PDF]

				A. W. Tolcher, D. Hao, J. de Bono, A. Miller, A. Patnaik, L. A. Hammond, L. Smetzer, J. Van Wart Hood, J. Merritt, E. K. Rowinsky, et al. Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer J. Clin. Oncol., May 1, 2006; 24(13): 2052 - 2058. [Abstract] [Full Text] [PDF]

				T. Fujiwara, N. Tanaka, S. Kanazawa, S. Ohtani, Y. Saijo, T. Nukiwa, K. Yoshimura, T. Sato, Y. Eto, S. Chada, et al. Multicenter Phase I Study of Repeated Intratumoral Delivery of Adenoviral p53 in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., April 10, 2006; 24(11): 1689 - 1699. [Abstract] [Full Text] [PDF]

				M. Fabbri, D. Iliopoulos, F. Trapasso, R. I. Aqeilan, A. Cimmino, N. Zanesi, S. Yendamuri, S.-Y. Han, D. Amadori, K. Huebner, et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo PNAS, October 25, 2005; 102(43): 15611 - 15616. [Abstract] [Full Text] [PDF]

				M. Nakase, M. Inui, K. Okumura, T. Kamei, S. Nakamura, and T. Tagawa p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome Mol. Cancer Ther., April 1, 2005; 4(4): 625 - 631. [Abstract] [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]

				S. Ohtani, S. Kagawa, Y. Tango, T. Umeoka, N. Tokunaga, Y. Tsunemitsu, J. A. Roth, Y. Taya, N. Tanaka, and T. Fujiwara Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo Mol. Cancer Ther., January 1, 2004; 3(1): 93 - 100. [Abstract] [Full Text]

				T. Terui, K. Murakami, R. Takimoto, M. Takahashi, K. Takada, T. Murakami, S. Minami, T. Matsunaga, T. Takayama, J. Kato, et al. Induction of PIG3 and NOXA through Acetylation of p53 at 320 and 373 Lysine Residues as a Mechanism for Apoptotic Cell Death by Histone Deacetylase Inhibitors Cancer Res., December 15, 2003; 63(24): 8948 - 8954. [Abstract] [Full Text] [PDF]

				C. Moon, Y. Oh, and J. A. Roth Current Status of Gene Therapy for Lung Cancer and Head and Neck Cancer Clin. Cancer Res., November 1, 2003; 9(14): 5055 - 5067. [Abstract] [Full Text] [PDF]

				M. Qin, S. Chen, T. Yu, B. Escuadro, S. Sharma, and R. K. Batra Coxsackievirus Adenovirus Receptor Expression Predicts the Efficiency of Adenoviral Gene Transfer into Non-Small Cell Lung Cancer Xenografts Clin. Cancer Res., October 15, 2003; 9(13): 4992 - 4999. [Abstract] [Full Text] [PDF]

				S. Frese, M. Schaper, J.-R. Kuster, D. Miescher, M. Jaattela, T. Buehler, and R. A. Schmid Cell death induced by down-regulation of heat shock protein 70 in lung cancer cell lines is p53-independent and does not require DNA cleavage J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 748 - 754. [Abstract] [Full Text] [PDF]

				F. F. Lang, J. M. Bruner, G. N. Fuller, K. Aldape, M. D. Prados, S. Chang, M. S. Berger, M. W. McDermott, S. M. Kunwar, L. R. Junck, et al. Phase I Trial of Adenovirus-Mediated p53 Gene Therapy for Recurrent Glioma: Biological and Clinical Results J. Clin. Oncol., July 1, 2003; 21(13): 2508 - 2518. [Abstract] [Full Text] [PDF]

				L. C. Pagliaro, A. Keyhani, D. Williams, D. Woods, B. Liu, P. Perrotte, J. W. Slaton, J. A. Merritt, H. B. Grossman, and C. P. Dinney Repeated Intravesical Instillations of an Adenoviral Vector in Patients With Locally Advanced Bladder Cancer: A Phase I Study of p53 Gene Therapy J. Clin. Oncol., June 15, 2003; 21(12): 2247 - 2253. [Abstract] [Full Text] [PDF]

				R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]

				M. Wierdl, C. L. Morton, L. C. Harris, M. K. Danks, J. D. Schuetz, and P. M. Potter p53-Mediated Regulation of Expression of a Rabbit Liver Carboxylesterase Confers Sensitivity to 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 699 - 705. [Abstract] [Full Text] [PDF]

				S. G. Swisher, J. A. Roth, R. Komaki, J. Gu, J. J. Lee, M. Hicks, J. Y. Ro, W. K. Hong, J. A. Merritt, K. Ahrar, et al. Induction of p53-regulated Genes and Tumor Regression in Lung Cancer Patients after Intratumoral Delivery of Adenoviral p53 (INGN 201) and Radiation Therapy Clin. Cancer Res., January 1, 2003; 9(1): 93 - 101. [Abstract] [Full Text] [PDF]

				G. K. Dy and A. A. Adjei Novel Targets for Lung Cancer Therapy: Part II J. Clin. Oncol., July 1, 2002; 20(13): 3016 - 3028. [Abstract] [Full Text] [PDF]

				C. G. Ferreira, M. Epping, F. A. E. Kruyt, and G. Giaccone Apoptosis: Target of Cancer Therapy Clin. Cancer Res., July 1, 2002; 8(7): 2024 - 2034. [Abstract] [Full Text] [PDF]

				H.-Y. Lee, K.-H. Chun, B. Liu, S. A. Wiehle, R. J. Cristiano, W. K. Hong, P. Cohen, and J. M. Kurie Insulin-like Growth Factor Binding Protein-3 Inhibits the Growth of Non-Small Cell Lung Cancer Cancer Res., June 1, 2002; 62(12): 3530 - 3537. [Abstract] [Full Text] [PDF]

				R. M. Bernal, S. Sharma, B. K. Gardner, J. T. Douglas, J. M. Bergelson, S. M. Dubinett, and R. K. Batra Soluble Coxsackievirus Adenovirus Receptor Is a Putative Inhibitor of Adenoviral Gene Transfer in the Tumor Milieu Clin. Cancer Res., June 1, 2002; 8(6): 1915 - 1923. [Abstract] [Full Text] [PDF]

				R. Oakley, E. Phillips, R. Hooper, D. Wilson, and M. Partridge A Preclinical Model of Minimal Residual Cancer in the Muscle Highlights Challenges Associated with Adenovirus-mediated p53 Gene Transfer Clin. Cancer Res., June 1, 2002; 8(6): 1984 - 1994. [Abstract] [Full Text] [PDF]

				A. Hemminki, K. R. Zinn, B. Liu, T. R. Chaudhuri, R. A. Desmond, B. E. Rogers, M. N. Barnes, R. D. Alvarez, and D. T. Curiel In Vivo Molecular Chemotherapy and Noninvasive Imaging With an Infectivity-Enhanced Adenovirus J Natl Cancer Inst, May 15, 2002; 94(10): 741 - 749. [Abstract] [Full Text] [PDF]

				Y. B. Dong, H. L. Yang, M. J. Elliott, and K. M. McMasters Adenovirus-mediated E2F-1 Gene Transfer Sensitizes Melanoma Cells to Apoptosis Induced by Topoisomerase II Inhibitors Cancer Res., March 1, 2002; 62(6): 1776 - 1783. [Abstract] [Full Text] [PDF]

				J. Kuball, S. F. Wen, J. Leissner, D. Atkins, P. Meinhardt, E. Quijano, H. Engler, B. Hutchins, D. C. Maneval, M. J. Grace, et al. Successful Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation J. Clin. Oncol., February 15, 2002; 20(4): 957 - 965. [Abstract] [Full Text] [PDF]

				M. Nishizaki, R. E. Meyn, L. B. Levy, E. N. Atkinson, R. A. White, J. A. Roth, and L. Ji Synergistic Inhibition of Human Lung Cancer Cell Growth by Adenovirus-mediated Wild-Type p53 Gene Transfer in Combination with Docetaxel and Radiation Therapeutics in Vitro and in Vivo Clin. Cancer Res., September 1, 2001; 7(9): 2887 - 2897. [Abstract] [Full Text] [PDF]

				A. Yver, J. J. Nemunaitis, and C. Cunningham Does Detection of Circulating ONYX-015 Genome by Polymerase Chain Reaction Indicate Vector Replication? J. Clin. Oncol., June 15, 2001; 19(12): 3155 - 3157. [Full Text] [PDF]

				M. Schuler, R. Herrmann, J. L.P. De Greve, A. K. Stewart, U. Gatzemeier, D. J. Stewart, L. Laufman, R. Gralla, J. Kuball, R. Buhl, et al. Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results of a Multicenter Phase II Study J. Clin. Oncol., March 15, 2001; 19(6): 1750 - 1758. [Abstract] [Full Text] [PDF]

				J. Nemunaitis, F. Khuri, I. Ganly, J. Arseneau, M. Posner, E. Vokes, J. Kuhn, T. McCarty, S. Landers, A. Blackburn, et al. Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer J. Clin. Oncol., January 15, 2001; 19(2): 289 - 298. [Abstract] [Full Text] [PDF]

				D.-C. Yu, Y. Chen, J. Dilley, Y. Li, M. Embry, H. Zhang, N. Nguyen, P. Amin, J. Oh, and D. R. Henderson Antitumor Synergy of CV787, a Prostate Cancer-specific Adenovirus, and Paclitaxel and Docetaxel Cancer Res., January 1, 2001; 61(2): 517 - 525. [Abstract] [Full Text]

				T. Waku, T. Fujiwara, J. Shao, T. Itoshima, T. Murakami, M. Kataoka, S. Gomi, J. A. Roth, and N. Tanaka Contribution of CD95 Ligand-Induced Neutrophil Infiltration to the Bystander Effect in p53 Gene Therapy for Human Cancer J. Immunol., November 15, 2000; 165(10): 5884 - 5890. [Abstract] [Full Text] [PDF]

				D. Weill, M. Mack, J. Roth, S. Swisher, S. Proksch, J. Merritt, and J. Nemunaitis Adenoviral-Mediated p53 Gene Transfer to Non-small Cell Lung Cancer Through Endobronchial Injection Chest, October 1, 2000; 118(4): 966 - 970. [Abstract] [Full Text] [PDF]